Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Primary central nervous system lymphoma (PCNSL) is a rare and aggressive subtype of diffuse large B-cell lymphoma (DLBCL).
• DLBCL relapsing to the central nervous system (CNS) presents significant treatment challenges.
• Bruton tyrosine kinase (BTK) is a key signaling molecule in B-cell malignancies.

Purpose of the Study:

• To evaluate the efficacy of ibrutinib, an irreversible BTK inhibitor, in patients with primary CNS lymphoma and secondary CNS DLBCL.
• To identify mechanisms of resistance to ibrutinib in these lymphomas.
• To explore combination strategies to overcome ibrutinib resistance.

Main Methods:

• Clinical evaluation of ibrutinib in patients with CNS DLBCL.
• Analysis of mutations (e.g., CD79B) and pathway activation (e.g., MTOR) in relation to treatment response.
• Preclinical studies combining ibrutinib with PI3K inhibitors (PIK3CA/PIK3CD).

Main Results:

• Ibrutinib demonstrated a high proportion of durable responses in primary CNS lymphoma and relapsed CNS DLBCL.
• Mutations in CD79B and MTOR pathway upregulation were associated with diminished response to ibrutinib.
• Preclinical combination therapy of PIK3CA/PIK3CD inhibitors with ibrutinib synergistically overcame resistance mechanisms.

Conclusions:

• Ibrutinib is a promising targeted therapy for CNS DLBCL, offering durable responses.
• Understanding resistance mechanisms involving CD79B and MTOR is crucial for optimizing treatment.
• Combination therapy with PI3K inhibitors presents a viable strategy to enhance efficacy and overcome resistance in this difficult-to-treat disease.